Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can)

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 330-335

  Ulmer, Hanno ^a   Bjørge, Tone ^b,c   Concin, Hans ^d   Lukanova, Annekatrin ^e   Manjer, Jonas ^f   Hallmans, Göran ^g   Borena, Wegene ^a   Häggström, Christel ^g   Engeland, Anders ^b,c   Almquist, Martin ^f   Jonsson, Håkan ^g   Selmer, Randi ^c   Stattin, Pär ^g,h   Tretli, Steinar ⁱ   Kleiner, Andrea ^j   Stocks, Tanja ^g,k   Nagel, Gabriele ^d,j  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF BERGEN   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d AGENCY FOR PREVENTIVE AND SOCIAL MEDICINE   (Austria)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g UMEÅ UNIVERSITY   (Sweden)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ CANCER REGISTRY OF NORWAY   (Norway)

^j UNIVERSITY OF ULM   (Germany)

^k The Capital Region   (Denmark)

more..

Author keywords

Cervical cancer; CONOR; Epidemiology; Metabolic factors

Indexed keywords

CHOLESTEROL; GLUCOSE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AUSTRIA; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CELL TRANSFORMATION, NEOPLASTIC; CHOLESTEROL; COHORT STUDIES; FEMALE; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; NORWAY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SWEDEN; TRIGLYCERIDES; UTERINE CERVICAL NEOPLASMS;

EID: 84859616958     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.052     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. [Internet]CA Cancer J Clin Feb. 4 2011 [cited 2011 Feb 21];Available from:http:// www.ncbi.nlm.nih.gov/pubmed/21296855.
2. van Dieren S, Beulens JWJ, van der SchouwYT, Grobbee DE,Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil May 2010;17(Suppl. 1):S3-8.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol Sep. 1999;189(1):12-9. (Pubitemid 29406813)
4. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol Apr. 2002;55(4):244-65. (Pubitemid 34293391)
5. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst Mar. 2 2011;103(5):368-83.
6. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol Nov. 2010;11(11): 1048-56.
7. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008 Oct;43(4 Suppl.) S5-25, S25.e1-41.
8. Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodill A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer Mar. 15 2006;118(6):1481-95.
9. Brinton LA, Herrero R, Reeves WC, de Britton RC, Gaitan E, Tenorio F. Risk factors for cervical cancer by histology. Gynecol Oncol Dec. 1993;51(3):301-6. (Pubitemid 24058602)
10. Lacey JV, Swanson CA, Brinton LA, Altekruse SF, Barnes WA, Gravitt PE, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer Aug. 15 2003;98(4):814-21. (Pubitemid 36959279)
11. Kapeu AS, Luostarinen T, Jellum E, Dillner J, Hakama M, Koskela P, et al. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol Feb. 15 2009;169(4):480-8.
12. Berrington de González A, Sweetland S, Green J. Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis. Br J Cancer May 4 2004;90(9):1787-91. (Pubitemid 38725654)
13. Green J, Berrington de Gonzalez A, Sweetland S, Beral V, Chilvers C, Crossley B, et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-control Study of Cervical Cancer. Br J Cancer Dec. 1 2003;89(11):2078-86. (Pubitemid 38030906)
14. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet Sep. 8 2007;370(9590):890-907. (Pubitemid 47371147)
15. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol Nov. 2006;169(5):1505-22. (Pubitemid 351181984)
16. Parazzini F, La Vecchia C, Negri E, Fasoli M, Cecchetti G. Risk factors for adenocarcinoma of the cervix: a case-control study. Br J Cancer Feb. 1988;57(2): 201-4. (Pubitemid 18085406)
17. Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, Diem G, et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer Oct. 6 2009;101(7):1202-6.
18. Ursin G, Pike MC, Preston-Martin S, d'Ablaing G, Peters RK. Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix: results from a population-based case-control study (California, United States). Cancer Causes Control May 1996;7(3):391-401. (Pubitemid 26163890)
19. Tulinius H, Sigfússon N, Sigvaldason H, Bjarnadóttir K, Tryggvadóttir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev Nov. 1997;6(11):863-73. (Pubitemid 27481633)
20. Tilg H, Moschen AR. Adipocytokines:mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol Oct. 2006;6(10):772-83. (Pubitemid 44453463)
21. Chung S-H, Franceschi S, Lambert PF. Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab Aug. 2010;21(8):504-11.
22. Baker R, Dauner JG, Rodriguez AC, Williams MC, Kemp TJ, Hildesheim A, et al. Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. Cytokine Mar. 2011;53(3):282-5.
23. Stocks T, Borena W, Strohmaier S, Bjørge T, Manjer J, Engeland A, et al. Cohort profile: the metabolic syndrome and cancer project (Me-Can). Int J Epidemiol Jun. 2010;39(3):660-7.
24. Bjørge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol Apr. 15 2010;171(8): 892-902.
25. Vizcaino AP, Moreno V, Bosch FX, Muñoz N, Barros-Dios XM, Borras J, et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer May 1 2000;86(3):429-35. (Pubitemid 30187507)
26. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ Jan. 21 1995;310(6973):170.
27. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol Aug. 15 1999;150(4):341-53. (Pubitemid 29383482)
28. Wood AM, White I, Thompson SG, Lewington S, Danesh J. Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int J Epidemiol Dec. 2006;35(6): 1570-8.
29. Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. Stat Med Mar. 30 2009;28(7): 1067-92.
30. Wolk A, Gridley G, Svensson M, Nyrén O, McLaughlin JK, Fraumeni JF, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control Jan. 2001;12(1):13-21. (Pubitemid 32125897)
31. Wee CC, Huang A, Huskey KW, McCarthy EP. Obesity and the likelihood of sexual behavioral risk factors for HPV and cervical cancer. Obesity (Silver Spring) Nov. 2008;16(11):2552-5.
32. Shen M-R, Hsu Y-M, Hsu K-F, Chen Y-F, Tang M-J, Chou C-Y. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling. Carcinogenesis May 2006;27(5):962-71.
33. Harris TG, Burk RD, Yu H, Minkoff H, Massad LS, Watts DH, et al. Insulin-like growth factor axis and oncogenic human papillomavirus natural history. Cancer Epidemiol Biomarkers Prev Jan. 2008;17(1):245-8. (Pubitemid 351196298)
34. Serrano M-L, Sánchez-Gómez M, Bravo M-M. Cervical scrapes levels of insulin-like growth factor-II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Horm Metab Res Dec. 2010;42(13):977-81.
35. Reimers LL, Anderson WF, Rosenberg PS, Henson DE, Castle PE. Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol Biomarkers Prev Mar. 2009;18(3): 792-800.
36. Kemp TJ, Hildesheim A, García-Piñeres A, Williams MC, Shearer GM, Rodriguez AC, et al. Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection. Cancer Epidemiol Biomarkers Prev Aug. 2010;19(8):1954-9.
37. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA Jan. 12 2005;293(2):194-202. (Pubitemid 40095870)
38. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985;38(5):435-41. (Pubitemid 15025864)
39. Iso H, Ikeda A, Inoue M, Sato S, Tsugane S. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer Dec. 1 2009;125(11): 2679-86.
40. Silcocks PB, Thornton-Jones H, Murphy M. Squamous and adenocarcinoma of the uterine cervix: a comparison using routine data. Br J Cancer Mar. 1987;55(3): 321-5. (Pubitemid 17036849)
41. Milsom I, Friberg LG. Primary adenocarcinoma of the uterine cervix. A clinical study. Cancer Sep. 1 1983;52(5):942-7.
42. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis Sep. 2008;29(9):1675-84.
43. Lebrecht A, Ludwig E, Huber A, Klein M, Schneeberger C, Tempfer C, et al. Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer. Gynecol Oncol Apr. 2002;85(1):32-5. (Pubitemid 34304006)
44. Dai Y, Zhang X, Peng Y, Wang Z. The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma. Gynecol Oncol Apr. 2005;97(1):96-103. (Pubitemid 40409497)
45. Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol Jan. 2011;19(1):33-9.
46. Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia May 2006;49(5):945-52.
47. Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer May 2009;45(7):1218-31.
48. Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009;48(1):27-33.